= .025), respectively. These results describe 2 clinically relevant distinct subtypes of pediatric AML. Similarly to other core-binding factor AMLs, patients with RUNX1-CBFA2T3 rearranged AML may benefit from stratification in the standard risk treatment, whereas patients with FUS-ERG rearranged AML should be considered high-risk.
No takes yet. Share an insight, caveat, or question.
Noort et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: